A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects with Cystic Fibrosis

Principal Investigator

Brian O'Sullivan

Study Number

STUDY02001566

Summary

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in participants with cystic fibrosis.

Phase

III

Available at the following location(s)

• Lebanon
• Manchester

View more details at ClinicalTrials.gov

Do you need help with some of the labels on this page?
Read our glossary of terms